NKTR logo

NKTR Nektar Therapeutics

NASDAQ Global Select · Biotechnology · Healthcare

$30.20
-2.34 (-7.19%)

Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cance…

Market Cap: $866.38Mwww.nektar.com

Price

No data yet.

Social Signal Score

53
5d
50
2 mentions
—
30d
53
6 mentions
—
60d
55
12 mentions
—
90d
55
13 mentions
—
news: 13

Analyst Ratings

33 analysts
Buyconsensus
Strong Buy 0Buy 22Hold 6Sell 5Strong Sell 0
Avg price target$107.2+255.0%
Low $50Median $130High $153
Current Consensus

Revenue

$9.39M-74.94%
$9.39M$368.83M$728.27M$1.09B
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-9.93
$-10.35–$-9.52
3 analysts
FY2026
$-7.35
$-8.54–$-6.73
12 analysts
FY2027
$-9.72
$-15.42–$-4.11
13 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Howard W. Robin
Sector
Healthcare
Industry
Biotechnology
Employees
63
Beta
1.15
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-2.26
www.nektar.com